Diligence memo · auto-generated · as of July 2, 2026

GLO Pharma, Inc.

GLO Pharma, Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

GLO Pharma, Inc. operates in Pharmaceuticals, based in Carlsbad.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

GLO Pharma, Inc. has raised $60M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).

Largest single filing: $53M on 2021-08-30.

Most recent recorded round closed around 2021-08-30.

Valuation (modeled)modeled

Provath models GLO Pharma, Inc. at approximately $1.2B (range $172M–$2.8B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.75× the median modeled value of Series C Pharmaceuticals companies in 2019–2021 (33 peers) — value vs value, same stage and era. Within the normal band (75% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 2 months.

Last raise 4.8 yr ago; this sector typically re-raises about every 13 months.

Silent for over 3× the sector's normal cadence.

The last round was 4.7× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 84% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 91% of those peers.

Closest niche peers: Verastem, Inc., Sentia Wellness, Inc., Oyster Point Pharma, Inc., Terns Pharmaceuticals, Inc., Theseus Pharmaceuticals, Inc..

Peoplefiled

13 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.